United Kingdom Cell Therapy Manufacturing Market Segmented By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, and Stem Cell Therapies), By Source of Cell (Autologous, Allogenic), By Scale of Operation (Preclinical, Clinical, and Commercial), By Source (In-House, Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, and Others),
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom Cell Therapy Manufacturing Market Segmented By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, and Stem Cell Therapies), By Source of Cell (Autologous, Allogenic), By Scale of Operation (Preclinical, Clinical, and Commercial), By Source (In-House, Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, and Others),
Cell therapy commonly known as regenerative medicine is a medical approach which involves transfer of autologous or allogeneic cellular material into a patient for treatment of disease and restore the normal functioning of tissues or organs. However, cell therapy manufacturing refers to the process of producing therapeutic cellular products such as dendritic cell vaccines which are used in cell-based therapies. Cell therapy manufacturing encompasses different approaches and techniques depending on the specific characteristics of the therapeutic cellular product and the intended application. Some common type of approaches comprises of autologous manufacturing, allogeneic manufacturing, centralized manufacturing, decentralized manufacturing, closed system manufacturing, and scalable manufacturing. Cell therapy manufacturing is a sequential process which involves certain steps such as cell sourcing, cell isolation and purification, cell expansion, cell manipulation and engineering, quality control, formulation, and administration. United Kingdom has been recognized as leading hub for life sciences and regenerative medicines, driving the research, development, and commercialization of cell-based therapies. There are around 21 cell therapy manufacturing organizations established in United Kingdom where 11 of them are dedicated to cell therapy sites, 8 organizations are focused on gene therapy sites and 7 therapies on multifunctional sites. Selected organizations which have emerged in accelerating the translation of scientific knowledge into clinical application includes advanced therapy treatment centers (ATTCs), cell and gene therapy catapult, and others. Certain factors are expected to drive the growth of United Kingdom cell therapy manufacturing market in the forecast period. Increase in prevalence of various chronic disorders such as cardiovascular diseases, neurological disorders, diabetes, autoimmune diseases, respiratory disorders, and renal diseases which require cell-based therapies for proper treatment are expected to register an impressive growth to United Kingdom cell therapy manufacturing market in upcoming years. Moreover, growing partnerships and agreements of supreme pharmaceutical companies in United Kingdom with a vision of combining the expertise of individual industries is also expected to propel the growth of cell therapy manufacturing market during forecast period. Rise in investments made by government for research and development of cell-based therapies is also a major driver which is expected to boost the growth of United Kingdom cell therapy manufacturing market in the forecast period.
Increase in Prevalence of Chronic Diseases
According to the analysis published by British Heart Foundation, it has been observed that, there are around 7.6 million people suffering from circulatory heart diseases in UK and 900,000 people are affected by heart attacks which leads to approximately 100,000 hospital admissions per year due to heart attack. Moreover, coronary heart diseases have further resulted in increased mortality rate in United Kingdom. Heart and circulatory diseases cause a quarter of all deaths in the UK which is more than 160,000 deaths each year. Strokes cause around 34,000 deaths every year and is the leading cause of severe disability in United Kingdom.
Growing Mergers and Acquisitions
Growing partnerships and agreements between leading pharmaceutical companies who are dedicated to combine the expertise of individual industries for improvising cell-based therapies are also expected to propel the growth of United Kingdom cell therapy manufacturing market in upcoming years. In 2021, Charles River Laboratories acquired a cell and gene therapy CDMO Cognate BioServices to enhance its manufacturing capabilities of cell and gene therapy. Moreover, in 2021, Thermo Fisher Scientific which a renowned medical provider of medical equipment acquired Henogen S.A. approximately USD 859.7 million which runs a viral vector manufacturing business in Belgium. This acquisition will increase its presence in the cell therapy manufacturing market. In 2019, Thermo Fisher Scientific also merged with Brammer Bio for USD 1.7 billion. Brammer Bio is a CDMO engaged in viral vector manufacturing for gene and cell therapies. Furthermore, in January 2022, Century Therapeutics and Bristol-Myers Squibb signed a license agreement and research collaboration to develop and commercialize four induced pluripotent stem cell-derived such as engineered natural killer cell or T-cell programs for solid tumors and hematologic malignancies.
Research and Development Investments
Cell and Gene Therapy Catapult is an ultimate initiative taken by United Kingdom research and innovation for scientific and economic development across the country. The group aims to highlight the development of UK cell-based therapies with 31% growth in funds raised by British advanced therapy developers of EUR 1.7 billion. Moreover, United Kingdom’s national innovation agency, Innovate UK invested up to EUR 16 million for developing UK commercial capacity to manufacture viral vectors. These viral vectors are used in the production of clinical cell and gene therapies for management of human disease and disorders. Furthermore, in 2020, United Kingdom government invested EUR 8.4 million in COVID-19 research projects with an approach to reveal more information about stem cell therapies as a treatment for disease. Henceforth, increase in investments Medical Research Council (MRC) for improving human health is further expected to register a lucrative growth to United Kingdom cell therapy manufacturing market in the forecast period.
Recent Developments
- In April 2022, Catalent acquired Erytech Pharma for its industrial-scale cell therapy manufacturing facility in Princeton, New Jersey. The deal includes an exclusive long-term supply partnership that will enable Catalent to promote ERYTECH's erythrocyte-based therapy Eryaspase (GRASPA) for acute lymphoblastic leukemia.
- In April 2022, Lonza added additional integrated capabilities for cell separation, bead removal, and cell attachment with the release of its second-generation instrument. This will help the company expand the capabilities of its Cocoon platform to include magnetic selection capabilities for cell therapy manufacturing.
United Kingdom cell therapy manufacturing market is segmented based on therapy, source of cell, scale of operation, source, application, end user, company, and region. In terms of therapy, the cell therapy manufacturing market is categorized into T-cell therapies, dendritic cell therapies, tumor cell therapies, and stem cell therapies. Based on, source of cell, United Kingdom cell therapy manufacturing market is divided into autologous and allogenic. Based on scale of operation, market is fragmented into preclinical, clinical, and commercial. On the basis of source, cell therapy manufacturing market is segmented into in-house and contract manufacturing. Based on application, United Kingdom cell therapy manufacturing market is categorized into oncology, cardiovascular diseases, orthopedic diseases, and others. Based on end user, market is fragmented into pharmaceutical & biotechnology companies, academic & research institutes, and others.
Market Players
Novartis Pharmaceuticals UK Ltd., Gilead Sciences, Ltd., Thermo Fisher Scientific Inc., Catalent, Inc., Oxford Biomedica plc., Amgen Limited, and Takeda Pharmaceutical Company Limited are some of the key players in United Kingdom cell therapy manufacturing market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume in tons, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Therapy Source of Cell Scale of Operation Source Application End User |
| Regional Scope | London, East Anglia, Southwest, Southeast, Scotland, East Midlands, Yorkshire & Humberside |
| Key Companies Profiled | Novartis Pharmaceuticals UK Ltd., Gilead Sciences, Ltd., Thermo Fisher Scientific Inc., Catalent, Inc., Oxford Biomedica plc., Amgen Limited, Takeda Pharmaceutical Company Limited |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy